MedPath

Assessment of excretion kinetics of urinary biomarkers after a single oral dose of zearalenone in healthy adults

Completed
Conditions
toxicology
study of the adverse effects of chemical substances on living organisms
Registration Number
NL-OMON49818
Lead Sponsor
Wageningen Food Safety Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

* Healthy subjects (self-reported), aged 18-65 years.

Exclusion Criteria

* Subjects with a BMI of 18.5 kg/m2 and below, or 30 kg/m2 and above.
* Subjects using prescribed medication during the duration of the study.
* Pregnant women or women intending to become pregnant during the duration of
the study.
* Breastfeeding women.
* Women menstruating at the anticipated days of sample collection.
* Intestinal, liver, biliary, or kidney disease, ileostomy, chronic diarrhea,
chronic constipation, celiac disease
* Occupation: working in or frequently visiting (>2d/week) grain silos or flour
factories.
* Working at WFSR.

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>concentrations of ZEN biomarkers (ZEN, *-ZEL, and *-ZEL, measured after<br /><br>enzymatic deconjugation) excreted in urine over ~72h after ingestion of a<br /><br>single dose of ZEN.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Not applicable.</p><br>
© Copyright 2025. All Rights Reserved by MedPath